RNA Supply Chain Videos

  1. mRNA Supply Chain And Critical Component Risks 10/16/2023

    What challenges do you consider the most formidable in your own mRNA therapeutic development environments?

  2. mRNA Raw Materials To Scale Up Your Manufacturing 11/22/2022

    Learn more about CustomBiotech's mRNA raw materials pipeline and strict quality criteria that are designed to support the success of our customers’ manufacturing scale-up and regulatory drug approval.

  3. What Does 2025 (And Beyond) Hold For The RNA-LNP Space? 12/4/2024

    Three LNP experts share their thoughts on the incremental advancements they’d like to see the RNA-LNP space make in the next few years.

  4. The 3 C's Of mRNA-LNP Material Sourcing

    In response to an audience poll question gauging which cGMP materials have proven the most difficult to source, our speakers provide additional clarity around which IVT & LNP-related materials today are more “commoditized”.

  5. Analytical Limitations In Assessing Plasmid Quality for mRNA Production 4/11/2025

    There remain a lot of gaps in our understanding of plasmid quality, particularly for high-quality mRNA production (as opposed to viral vector production). In this segment of a recent Advancing RNA Live panel, speakers Adi Nair, Tyler Goodwin, and April Sena highlight their biggest questions around plasmid DNA quality, as well as the pros and cons of some of the analytical methods upon which we’re relying most heavily today to assess plasmid quality.

  6. Why Our Conversations About Supply Chain Should NOT Overlook This Key Aspect

    When asked which specific topic they’d like to see discussed more regularly in the future as it relates to our supply chains, Featured speakers for the "Got Raw Materials? The State Of The mRNA Supply Chain" event were aligned around this one absolutely critical topic...

  7. Why Current dsRNA Analytics Don't Quite Cut It 10/15/2025

    In this Advancing RNA Live segment, several speakers raise concerns about the industry's ability to accurately measure impurities, particularly dsRNA, arguing that current analytics are insufficient, especially for high-dose therapeutics.

  8. Can A Small Plasmid Produce Huge Benefits? The Power Of Small 1/17/2023

    With benefits across applications, nanoplasmids are designed to replace antiquated bacterial backbones, while eliminating antibiotic markers that can cause regulatory concerns.

  9. Synthetic pDNA: Is It Ready For mRNA Production Primetime? 4/11/2025

    Together, this Advancing RNA panel briefly addresses the ongoing rise of synthetic pDNA, sharing the current benefits and limitations of working with this technology for plasmid production today.

  10. Don't Ignore These Functional Areas In Your RNA Therapeutic's Regulatory Story 5/10/2024

    Explore two functional areas that Advancing RNA panelists consider most essential to telling an RNA product’s “story” thoroughly to regulators.